Founded in 2019, Delfi Diagnostics is committed to developing high-performing, affordable blood tests for early detection of cancer across multiple tumor types. Leveraging recent advances in cancer biology and machine learning, DELFI's technology can achieve high performance from low-cost, widely available sequencing technology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/12/21 | $100,000,000 | Series A |
AV8 Ventures Cowen Healthcare Investments Foresite Capital Illumina Ventures Menlo Ventures Northpond Ventures OrbiMed Advisors  Rock Springs Capital Samsara BioCapital T. Rowe Price Associates Windham Venture Partners | undisclosed |
| 07/18/22 | $225,000,000 | Series B |
AV8 Ventures Brown Advisory Cowen Healthcare Investments DFJ Growth Eli Lilly and Company Foresite Capital Initiate Ventures Menlo Ventures Northpond Ventures Open Field Capital OrbiMed Advisors Point Field Partners Point72 Ventures PTX Capital Rock Springs Capital Samsara BioCapital T. Rowe Price Associates | undisclosed |
